Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 8/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 8/20 | 0.37 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772292 | 0.83 | PRMT5 (0.45) | NTRK1GSK3BKITPRMT5WDR77 | |
| SCHEMBL19669099 | 0.81 | CYP2C19 (0.37) | KIT | |
| SCHEMBL21017779 | 0.81 | DYRK1A (0.34) | GSK3BMAP3K11DYRK1ACLK1DYRK2 | |
| SCHEMBL24197700 | 0.79 | GSK3A (0.37) | GSK3BKITMAP3K11DYRK1ACLK1 | |
| SCHEMBL26775127 | 0.79 | DYRK1A (0.40) | MAP3K11DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL18858487 | 0.79 | AURKA (0.50) | NTRK1GSK3BDYRK1ADYRK1B | |
| SCHEMBL18352451 | 0.77 | MAP3K12 (0.35) | DYRK1ACLK1 | |
| SCHEMBL25111074 | 0.77 | POLB (0.37) | DYRK1ACLK1PRMT5WDR77 | |
| SCHEMBL25139536 | 0.77 | AXL (0.33) | DYRK1ACLK1PIK3CAPRMT5WDR77 | |
| SCHEMBL10269012 | 0.77 | MET (0.43) | NTRK1GSK3BKITMAP3K11DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338452-B2 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Bio Pharma Inc. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2265608-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | NTRK1 633/4885GSK3B 94/4885KIT 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.